Research
Article overview
-
The role of B lymphocytes in the progression of chronic immune-mediated neuropathies
-
Study on CIDP
In addition, I am studying the role of B lymphocytes in the progression of chronic immune-mediated neuropathies, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Autoimmune Nodopathy (AN). Through this research, we strive to enhance diagnostics, clinical care, and treatment options for patients affected by these conditions.
-
-
Detecting anti-paranodal antibodies
-
Study on GBS
My research primarily focuses on investigating novel pathogenic antibodies in paranodal regions associated with immune-mediated neuropathies. The aim of my project is to improve diagnostic methods for detecting anti-paranodal antibodies and to determine the prevalence of these harmful autoantibodies in patients with Guillain-Barré Syndrome (GBS).
-
-
Time to treatment study
-
Study on GBS
In this project, we aim to describe the current practice of time to treatment. We also assess the association with functional outcome in patients with GBS who received first-line treatment with intravenous immunoglobulin or plasma exchange. This study is performed using data from the International GBS Outcome Study (IGOS).
-
-
PK-PD modelling in patients with CIDP.
-
Study on CIDP
The optimal maintenance dosing regimen of intravenous immunoglobulin (IVIg) varies between patients with CIDP. At present, there is only limited information available on the pharmacokinetics (PK) of IVIg treatment in patients with CIDP. In this study we want to describe the PK of IVIg induction and maintenance treatment in patients with CIDP using non-linear mixed […]
-
-
Fc-gamma receptor (FcγR) polymorphisms and predisposition to develop GBS.
-
Study on GBS
FcγRs are important for the effector functions of immunoglobulin G (IgG) and are therefore expected to play a role in the pathophysiology of GBS. In this study, we identify the prevalence of genetic polymorphisms in the FCGR2/3 locus in patients with GBS using multiplex ligation-dependent probe amplification (MLPA). We aim to investigate whether certain genetic […]
-
-
Should we individualize IVIG treatment in patients with GBS?
-
Study on GBS
A significant number of patients with GBS does not respond to the arbitrarily defined standard dosing regimen of intravenous immunoglobulin (IVIg). In this study, we aim to investigate the relationship between the pharmacokinetics (PK) – what the body does to the drug – and the clinical outcome (pharmacodynamics). The goal is to identify patients who […]
-
-
Prediction of chronic axonal polyneuropathy.
-
Study on Chronic Axonal Polyneuropathy
By longitudinal assessment of participants, we aim to find symptoms or features (risk-factors) preceding the development of chronic axonal polyneuropathy.
-
-
Early detection of chronic axonal polyneuropathy
-
Study on Chronic Axonal Polyneuropathy
We will study the use of the Erasmus Polyneuropathy Screening Score (E-PSS) at a population level, as early detection of polyneuropathy is important.
-
-
Is CIAP a solitary disorder?
-
Study on Chronic Axonal Polyneuropathy
Assessing whether CIAP is a solitary disorder of peripheral nerves or part of a more generalized disease involving also other organs and multimorbidity.
-
-
Identification of novel modifiable risk factors
-
Study on Chronic Axonal Polyneuropathy
We aim to investigate associations between frequently used medication and polyneuropathy as well as lifestyle factors.
-
-
Mimics of GBS in The Netherlands
-
Study on GBS
Accurate and rapid diagnosis of GBS is important for adequate monitoring and treatment of patients. Since there is no definitive test, the diagnosis is based on clinical symptoms and signs found during neurological examination. Early diagnosis is often difficult due to the large diversity in symptoms and course of the disease. Furthermore, other diseases can […]
-
-
Early recognition of GBS with fluctuations and acute-onset CIDP
-
Study on CIDP and GBS
In 10% of the patients with GBS, secondary fluctuations occur and in 5% the diagnosis is eventually changed to acute-onset CIDP (A-CIDP). Early recognition of patients at risk for fluctuations or A-CIDP is important, because alternative treatment options can be considered in these patients. In this study, we aim to describe the clinical features of […]
-
